Vannappagari V, et al. - Researchers sought to evaluate birth outcomes associated with maternal dolutegravir treatment during pregnancy via reviewing 2 large, independent antiretroviral pregnancy registries [Antiretroviral Pregnancy Registry (APR) and the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC)]. The analyses provide important safety information for use of dolutegravir-based regimens during early pregnancy as dolutegravir was initiated during or before the first trimester (including 158 outcomes after dolutegravir exposure at conception) for most pregnancies included in these analyses (APR, 65%; EPPICC, 58%). Live births were reported in more than 90% of pregnancies from both data sets. Women exposed to dolutegravir reported induced and spontaneous abortions primarily during their first trimester of pregnancy (as expected because most abortions occur in the first trimester). Compared to recent estimates among general populations, APR (2.3% and 4.2%, respectively) and EPPICC (both 1.2%) cohorts who received dolutegravir had lower rates of both induced and spontaneous abortions.